Ganciclovir (Par Pharmaceutical, Inc.)
Welcome to the PulseAid listing for the Ganciclovir drug offered from Par Pharmaceutical, Inc.. This Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],DNA Polymerase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient],Nucleoside Analog Antiviral [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Par Pharmaceutical, Inc. |
| NON-PROPRIETARY NAME: | ganciclovir |
| SUBSTANCE NAME: | GANCICLOVIR SODIUM |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],DNA Polymerase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient],Nucleoside Analog Antiviral [EPC] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2017-03-31 |
| END MARKETING DATE: | 0000-00-00 |
Ganciclovir HUMAN PRESCRIPTION DRUG Details:
| Item Description | Ganciclovir from Par Pharmaceutical, Inc. |
| LABELER NAME: | Par Pharmaceutical, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 500(mg/10mL) |
| START MARKETING DATE: | 2017-03-31 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 42023-173_b1223513-dcea-4e25-a5fa-87611ecfe67b |
| PRODUCT NDC: | 42023-173 |
| APPLICATION NUMBER: | ANDA204950 |
Other GANCICLOVIR SODIUM Pharmaceutical Manufacturers / Labelers:
